Thomas Cahill, M.D., Ph.D., is the founder and managing partner of Newpath Partners. See contact routes.
Thomas Cahill, M.D., Ph.D., is the founder and managing partner of Newpath Partners, a Boston-based venture capital firm he established in 2018 to build biotechnology companies from the ground up. His investment thesis centers on partnering with leading academic scientists to translate groundbreaking discoveries into transformative therapies, focusing exclusively on life sciences and biotechnology at the Series A stage, with participation in seed and selective Series B rounds. Newpath typically acts as a founding investor with substantial check sizes, averaging $88.7 million historically and reaching up to $400 million, leveraging its company-formation model to provide capital plus operational expertise. Notable portfolio companies include Prime Medicine, Chroma Medicine, Autobahn Therapeutics, and Metsera, all built through this ground-up approach. Cahill’s distinctive point of view is that venture capital should create companies rather than merely fund them, uniquely aligning interests among academics, investors, and management teams. He has publicly applied this expertise through initiatives like Scientists to Stop COVID-19, a coalition he helped es
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in Boston.
Investors like Thomas Cahill · Full investor directory · Investor access · Company funding database